Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [

Aged Carcinoma, Squamous Cell / diagnostic imaging Female Fibroblasts Fluorodeoxyglucose F18 Head and Neck Neoplasms Humans Lymph Nodes Magnetic Resonance Imaging Male Middle Aged Mouth Neoplasms / diagnostic imaging Positron Emission Tomography Computed Tomography Positron-Emission Tomography Quinolines Radiopharmaceuticals Sensitivity and Specificity
Fibroblast activation protein Head and neck cancer Molecular imaging PET

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
11 2021
Historique:
received: 03 02 2021
accepted: 19 05 2021
pubmed: 30 5 2021
medline: 21 10 2021
entrez: 29 5 2021
Statut: ppublish

Résumé

While [ Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [ [ FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted.

Identifiants

DOI: 10.1007/s00259-021-05422-z PMID: 34050405 PMC: PMC8484183
pubmed: 34050405
doi: 10.1007/s00259-021-05422-z
pii: 10.1007/s00259-021-05422-z
pmc: PMC8484183
doi:

Substances chimiques

68Ga-FAPI 0
Quinolines 0
Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3951-3960

Informations de copyright

© 2021. The Author(s).

Références

Hernandez-Guerrero JC, Jacinto-Aleman LF, Jimenez-Farfan MD, Macario-Hernandez A, Hernandez-Flores F, Alcantara-Vazquez A. Prevalence trends of oral squamous cell carcinoma. Mexico City’s General Hospital experience. Med Oral Patol Oral Cir Bucal. 2013;18:e306-11.
doi: 10.4317/medoral.18043
Sadick M, Schoenberg SO, Hoermann K, Sadick H. Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer. GMS Curr Topics Otorhinolaryngol Head Neck Surg. 2012;11:Doc08. https://doi.org/10.3205/cto000090 .
doi: 10.3205/cto000090
Bagan J, Sarrion G, Jimenez Y. Oral cancer: clinical features. Oral Oncol. 2010;46:414–7. https://doi.org/10.1016/j.oraloncology.2010.03.009 .
doi: 10.1016/j.oraloncology.2010.03.009 pubmed: 20400366
Tandon P, Dadhich A, Saluja H, Bawane S, Sachdeva S. The prevalence of squamous cell carcinoma in different sites of oral cavity at our Rural Health Care Centre in Loni, Maharashtra - a retrospective 10-year study. Contemp Oncol (Pozn). 2017;21:178–83. https://doi.org/10.5114/wo.2017.68628 .
doi: 10.5114/wo.2017.68628
DiTroia JF. Nodal metastases and prognosis in carcinoma of the oral cavity. Otolaryngol Clin North Am. 1972;5:333–42.
doi: 10.1016/S0030-6665(20)32999-6
Kumar T, Patel MD. Pattern of lymphatic metastasis in relation to the depth of tumor in oral tongue cancers: a clinico pathological correlation. Indian J Otolaryngol Head Neck Surg. 2013;65:59–63. https://doi.org/10.1007/s12070-012-0504-y .
doi: 10.1007/s12070-012-0504-y pubmed: 24427617
Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg. 2004;131:472–6. https://doi.org/10.1016/j.otohns.2004.04.008 .
doi: 10.1016/j.otohns.2004.04.008 pubmed: 15467620
Teichgraeber JF, Clairmont AA. The incidence of occult metastases for cancer of the oral tongue and floor of the mouth: treatment rationale. Head Neck Surg. 1984;7:15–21.
doi: 10.1002/hed.2890070105
Haigentz M Jr, Hartl DM, Silver CE, Langendijk JA, Strojan P, Paleri V, et al. Distant metastases from head and neck squamous cell carcinoma Part III. Treat Oral Oncol. 2012;48:787–93. https://doi.org/10.1016/j.oraloncology.2012.03.019 .
doi: 10.1016/j.oraloncology.2012.03.019 pubmed: 22516376
de Bree R, Castelijns JA, Hoekstra OS, Leemans CR. Advances in imaging in the work-up of head and neck cancer patients. Oral Oncol. 2009;45:930–5. https://doi.org/10.1016/j.oraloncology.2009.07.011 .
doi: 10.1016/j.oraloncology.2009.07.011 pubmed: 19692289
Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4. https://doi.org/10.1245/s10434-010-0985-4 .
doi: 10.1245/s10434-010-0985-4 pubmed: 20180029
Huang SH, O’Sullivan B. Overview of the 8th Edition TNM classification for head and neck cancer. Curr Treat Options Oncol. 2017;18:40. https://doi.org/10.1007/s11864-017-0484-y .
doi: 10.1007/s11864-017-0484-y pubmed: 28555375
Cho JK, Ow TJ, Lee AY, Smith RV, Schlecht NF, Schiff BA, et al. Preoperative (18)F-FDG-PET/CT vs contrast-enhanced CT to identify regional nodal metastasis among patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2017;157:439–47. https://doi.org/10.1177/0194599817703927 .
doi: 10.1177/0194599817703927 pubmed: 28608737 pmcid: 6372372
Dammann F, Horger M, Mueller-Berg M, Schlemmer H, Claussen CD, Hoffman J, et al. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol. 2005;184:1326–31. https://doi.org/10.2214/ajr.184.4.01841326 .
doi: 10.2214/ajr.184.4.01841326 pubmed: 15788619
Hirshoren N, Olayos E, Herschtal A, Ravi Kumar AS, Gyorki DE. Preoperative positron emission tomography for node-positive head and neck cutaneous squamous cell carcinoma. Otolaryngol Head Neck Surg. 2018;158:122–6. https://doi.org/10.1177/0194599817731735 .
doi: 10.1177/0194599817731735 pubmed: 28925330
Krabbe CA, Balink H, Roodenburg JL, Dol J, de Visscher JG. Performance of 18F-FDG PET/contrast-enhanced CT in the staging of squamous cell carcinoma of the oral cavity and oropharynx. Int J Oral Maxillofac Surg. 2011;40:1263–70. https://doi.org/10.1016/j.ijom.2011.06.023 .
doi: 10.1016/j.ijom.2011.06.023 pubmed: 21824748
Subramaniam RM, Agarwal A, Colucci A, Ferraro R, Paidpally V, Mercier G. Impact of concurrent diagnostic level CT with PET/CT on the utilization of stand-alone CT and MRI in the management of head and neck cancer patients. Clin Nucl Med. 2013;38:790–4. https://doi.org/10.1097/RLU.0b013e31829f8ca5 .
doi: 10.1097/RLU.0b013e31829f8ca5 pubmed: 23917783
Wallowy P, Diener J, Grunwald F, Kovacs AF. 18F-FDG PET for detecting metastases and synchronous primary malignancies in patients with oral and oropharyngeal cancer. Nuklearmedizin. 2009;48:192-9; quiz N42. https://doi.org/10.3413/nukmed-0242 .
Kircher M, Lapa C. Infection and inflammation imaging: beyond FDG. PET Clin. 2020;15:215–29. https://doi.org/10.1016/j.cpet.2019.11.004 .
doi: 10.1016/j.cpet.2019.11.004 pubmed: 32145892
Plaxton NA, Brandon DC, Corey AS, Harrison CE, KaragulleKendi AT, Halkar RK, et al. Characteristics and limitations of FDG PET/CT for imaging of squamous cell carcinoma of the head and neck: a comprehensive review of anatomy, metastatic pathways, and image findings. AJR Am J Roentgenol. 2015;205:W519–31. https://doi.org/10.2214/AJR.14.12828 .
doi: 10.2214/AJR.14.12828 pubmed: 26496574
Bae JY, Kim EK, Yang DH, Zhang X, Park YJ, Lee DY, et al. Reciprocal interaction between carcinoma-associated fibroblasts and squamous carcinoma cells through interleukin-1alpha induces cancer progression. Neoplasia. 2014;16:928–38. https://doi.org/10.1016/j.neo.2014.09.003 .
doi: 10.1016/j.neo.2014.09.003 pubmed: 25425967 pmcid: 4240921
Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y, et al. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 2014;5:e1155. https://doi.org/10.1038/cddis.2014.122 .
doi: 10.1038/cddis.2014.122 pubmed: 24722280 pmcid: 5424105
Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994;91:5657–61. https://doi.org/10.1073/pnas.91.12.5657 .
doi: 10.1073/pnas.91.12.5657 pubmed: 7911242 pmcid: 44055
Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87:7235–9. https://doi.org/10.1073/pnas.87.18.7235 .
doi: 10.1073/pnas.87.18.7235 pubmed: 2402505 pmcid: 54718
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11:257–66. https://doi.org/10.1158/1535-7163.MCT-11-0340 .
doi: 10.1158/1535-7163.MCT-11-0340 pubmed: 22323494 pmcid: 3586189
Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS ONE. 2015;10:e0116683. https://doi.org/10.1371/journal.pone.0116683 .
doi: 10.1371/journal.pone.0116683 pubmed: 25775399 pmcid: 4361589
Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E, Bamberger U, et al. Expression of the fibroblast activation protein during mouse embryo development. Int J Dev Biol. 2001;45:445–7.
pubmed: 11330865
Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22. https://doi.org/10.2967/jnumed.118.210443 .
doi: 10.2967/jnumed.118.210443 pubmed: 29626119
Luo Y, Pan Q, Zhang W. IgG4-related disease revealed by (68)Ga-FAPI and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2019;46:2625–6. https://doi.org/10.1007/s00259-019-04478-2 .
doi: 10.1007/s00259-019-04478-2 pubmed: 31410541
Luo Y, Pan Q, Zhang W, Li F. Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in 68Ga-FAPI PET/CT. Clin Nucl Med. 2020;45:310–1. https://doi.org/10.1097/rlu.0000000000002914 .
doi: 10.1097/rlu.0000000000002914 pubmed: 31977474
Pan Q, Luo Y, Zhang W. Recurrent immunoglobulin G4-related disease shown on 18F-FDG and 68Ga-FAPI PET/CT. Clin Nucl Med. 2020;45:312–3. https://doi.org/10.1097/rlu.0000000000002919 .
doi: 10.1097/rlu.0000000000002919 pubmed: 31977476
Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Götz TI, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79:1485–91. https://doi.org/10.1136/annrheumdis-2020-217408 .
doi: 10.1136/annrheumdis-2020-217408 pubmed: 32719042
Hao B, Wu X, Pang Y, Sun L, Wu H, Huang W, et al. [(18)F]FDG and ([68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. Eur J Nucl Med Mol Imaging. 2021;48:651–2. https://doi.org/10.1007/s00259-020-04941-5 .
doi: 10.1007/s00259-020-04941-5 pubmed: 32643006
Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, et al. Neck dissection classification update: revisions proposed by the American head and neck society and the American academy of otolaryngology-head and neck surgery. Arch Otolaryngol Head Neck Surg. 2002;128:751–8.
doi: 10.1001/archotol.128.7.751
Campbell RS, Baker E, Chippindale AJ, Wilson G, McLean N, Soames JV, et al. MRI T staging of squamous cell carcinoma of the oral cavity: radiological-pathological correlation. Clin Radiol. 1995;50:533–40. https://doi.org/10.1016/s0009-9260(05)83187-3 .
doi: 10.1016/s0009-9260(05)83187-3 pubmed: 7656519
Trotta BM, Pease CS, Rasamny JJ, Raghavan P, Mukherjee S. Oral cavity and oropharyngeal squamous cell cancer: key imaging findings for staging and treatment planning. Radiographics Rev Publ Radiol Soc North Am Inc. 2011;31:339–354. https://doi.org/10.1148/rg.312105107 .
Forghani R, Yu E, Levental M, Som PM, Curtin HD. Imaging evaluation of lymphadenopathy and patterns of lymph node spread in head and neck cancer. Expert Rev Anticancer Ther. 2015;15:207–24. https://doi.org/10.1586/14737140.2015.978862 .
doi: 10.1586/14737140.2015.978862 pubmed: 25385488
Som PM, Curtin HD, Mancuso AA. Imaging-based nodal classification for evaluation of neck metastatic adenopathy. AJR Am J Roentgenol. 2000;174:837–44. https://doi.org/10.2214/ajr.174.3.1740837 .
doi: 10.2214/ajr.174.3.1740837 pubmed: 10701636
Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13:1736–41. https://doi.org/10.1158/1078-0432.CCR-06-1746 .
doi: 10.1158/1078-0432.CCR-06-1746 pubmed: 17363526
Serfling S, Zhi Y, Schirbel A, Lindner T, Meyer T, Gerhard-Hartmann E, et al. Improved cancer detection in Waldeyer’s tonsillar ring by (68)Ga-FAPI PET/CT imaging. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05055-8 .
doi: 10.1007/s00259-020-05055-8 pubmed: 33111182 pmcid: 8113141
Pentenero M, Cistaro A, Brusa M, Ferraris MM, Pezzuto C, Carnino R, et al. Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head Neck. 2008;30:1488–96. https://doi.org/10.1002/hed.20906 .
doi: 10.1002/hed.20906 pubmed: 18767178
Lowe VJ, Duan F, Subramaniam RM, Sicks JD, Romanoff J, Bartel T, et al. Multicenter Trial of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography staging of head and neck cancer and negative predictive value and surgical impact in the N0 neck: results from ACRIN 6685. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:1704–12. https://doi.org/10.1200/jco.18.01182 .
doi: 10.1200/jco.18.01182
Yongkui L, Jian L, Wanghan, Jingui L. 18FDG-PET/CT for the detection of regional nodal metastasis in patients with primary head and neck cancer before treatment: a meta-analysis. Surg Oncol. 2013;22:e11-6. https://doi.org/10.1016/j.suronc.2013.02.002 .
doi: 10.1016/j.suronc.2013.02.002 pubmed: 23538049
Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020;47:2836–45. https://doi.org/10.1007/s00259-020-04859-y .
doi: 10.1007/s00259-020-04859-y pubmed: 32447444 pmcid: 7567680
Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92. https://doi.org/10.2967/jnumed.118.215913 .
doi: 10.2967/jnumed.118.215913 pubmed: 30072500 pmcid: 6424229
Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein-targeted PET/CT with (68)Ga-FAPI for imaging IgG4-related disease: comparison to (18)F-FDG PET/CT. J Nucl Med. 2021;62:266–71. https://doi.org/10.2967/jnumed.120.244723 .
doi: 10.2967/jnumed.120.244723 pubmed: 32513902
Pure E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57. https://doi.org/10.1038/s41388-018-0275-3 .
doi: 10.1038/s41388-018-0275-3 pubmed: 29720723 pmcid: 6092565

Auteurs

Christian Linz (C)

Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.

Roman C Brands (RC)

Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.

Olivia Kertels (O)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Institute for Diagnostic and Interventional Radiology, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.

Alexander Dierks (A)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.
Nuclear Medicine, Medical Faculty, University of Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany.

Joachim Brumberg (J)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany.

Elena Gerhard-Hartmann (E)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Department of Pathology, University of Würzburg, Josef-Schneider-Str.2, 97080, Würzburg, Germany.

Stefan Hartmann (S)

Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.

Andreas Schirbel (A)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.

Sebastian Serfling (S)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.

Yingjun Zhi (Y)

Department of Otorhinolaryngology, University Hospital of Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Germany.

Andreas K Buck (AK)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.

Alexander Kübler (A)

Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.

Julian Hohm (J)

Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.

Constantin Lapa (C)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany. constantin.lapa@uk-augsburg.de.
Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany. constantin.lapa@uk-augsburg.de.
Nuclear Medicine, Medical Faculty, University of Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany. constantin.lapa@uk-augsburg.de.
ORCID: 0000-0001-7536-2207

Malte Kircher (M)

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Josef-Schneider-Str. 6, 97080, Würzburg, Germany.
Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.
Nuclear Medicine, Medical Faculty, University of Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany.
ORCID: 0000-0003-4355-0881

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Targeting fibroblast activation protein in...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs épidermoïdes › Carcinome épidermoïde › Targeting fibroblast activation protein in...
questionsmedicales.fr › Cellules › Cellules du tissu conjonctif › Fibroblastes › Targeting fibroblast activation protein in...
questionsmedicales.fr › Glucides › Désoses › Désoxyglucose › Fluorodésoxyglucose F18 › Targeting fibroblast activation protein in...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Targeting fibroblast activation protein in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting fibroblast activation protein in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système lymphatique › Tissu lymphoïde › Noeuds lymphatiques › Targeting fibroblast activation protein in...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Targeting fibroblast activation protein in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Targeting fibroblast activation protein in...
questionsmedicales.fr › Maladies du système stomatognathique › Maladies de la bouche › Tumeurs de la bouche › Targeting fibroblast activation protein in...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Targeting fibroblast activation protein in...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Targeting fibroblast activation protein in...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Targeting fibroblast activation protein in...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Targeting fibroblast activation protein in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Sensibilité et spécificité › Targeting fibroblast activation protein in...